Effects of chronic administration of valproic acid to epileptic patients on coagulation tests and primary hemostasis. (11th March 2015)

• Record Type: Journal Article
• Authors: Zighetti, Maddalena L.; Fontana, Gessica; Lussana, Federico; Chiesa, Valentina; Vignoli, Aglaia; Canevini, Maria Paola; Cattaneo, Marco
• Is Part Of: Epilepsia. Volume 56:issue 5(2015:May)
• Page Start: e49
• Page End: e52
• Publication Date: 2015-03-11
• Subjects: Epilepsy -- Periodicals; 616.853
• DOI: 10.1111/epi.12952
• Languages: English
• ISSNs: 0013-9580

Abstract

<abstract abstract-type="main" id="epi12952-abs-0001"> <title>Summary</title> <p>Valproic acid (VPA) is an antiepileptic drug that has been associated with impaired hemostasis and increased risk for postsurgical bleeding. However, the published reports provide controversial results. We measured parameters of primary hemostasis in VPA‐treated patients with epilepsy, focusing on adenosine nucleotide–dependent platelet responses, which play a central role in primary hemostasis. We enrolled 20 cases (epileptic patients receiving treatment with VPA) and 20 controls (12 epileptic patients receiving treatment with drugs different from VPA and 8 healthy subjects). Measurements included prothrombin time (PT), activated partial thromboplastin time (APTT), platelet count, platelet function analyzer (PFA)‐100 closure times, plasma von Willebrand factor levels, platelet content of ADP, ATP, and serotonin (all stored in platelet dense granules), and platelet shape change and aggregation induced by ADP and other platelet agonists, including the ATP analog α, β‐methylene‐ATP. The plasma concentration of VPA was in the therapeutic range in 17 patients and slightly above the upper limit in 3 patients. There were no statistically significant differences in any of the studied parameters in cases versus controls. Our thorough controlled study failed to show that chronic treatment with VPA induces significant abnormalities of coagulation and primary hemostasis. Therefore, VPA, when present in the circulation in the therapeutic range, does not impair hemostasis.</p> </abstract>